In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Right to Try Act''.

SEC. 2. USE OF UNAPPROVED MEDICAL PRODUCTS BY PATIENTS DIAGNOSED WITH A 
              TERMINAL ILLNESS.

    (a) In General.--Notwithstanding the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 301 et seq.), the Controlled Substances Act (21 
U.S.C. 801 et seq.), and any other provision of Federal law, the 
Federal Government shall not take any action to prohibit or restrict--
            (1) the production, manufacture, distribution, prescribing, 
        or dispensing of an experimental drug, biological product, or 
        device that--
                    (A) is intended to treat a patient who has been 
                diagnosed with a terminal illness; and
                    (B) is authorized by, and in accordance with, State 
                law; and
            (2) the possession or use of an experimental drug, 
        biological product, or device--
                    (A) that is described in subparagraphs (A) and (B) 
                of paragraph (1); and
                    (B) for which the patient has received a 
                certification from the patient's treating physician in 
                accordance with subsection (b).
    (b) Physician Certification.--A certification by the patient's 
treating physician referred to in subsection (a)(2)(B) must include 
each of the following:
            (1) A certification that the physician--
                    (A) is in good standing with the physician's 
                certifying organization or board; and
                    (B) has personally examined the patient.
            (2) A certification that there is no reason to conclude the 
        experimental drug, biological product, or device poses an 
        unreasonable and significant risk of danger to the patient.
            (3) A certification that the patient has been diagnosed 
        with a terminal disease or condition and does not have any 
        treatment options that--
                    (A) are comparable to treatment using the 
                experimental drug, biological product, or device or 
                otherwise satisfactory; and
                    (B) are approved, licensed, or cleared for 
                commercial distribution under section 505, 510(k), or 
                515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262) and are 
                available to diagnose, monitor, or treat the patient's 
                disease or condition.
            (4) A certification that the probable risk to the patient 
        from the experimental drug, biological product, or device is 
        not greater than the probable risk from the patient's disease 
        or condition.
            (5) A certification that the physician has provided the 
        patient with a written statement and oral explanation of the 
        medical treatment to be provided using the experimental drug, 
        biological product, or device.
            (6) An acknowledgement signed by the patient (or the 
        patient's legal representative) that the physician has provided 
        the written statement and oral explanation required by 
        paragraph (5), and has disclosed the following:
                    (A) That the medical treatment using the 
                experimental drug, biological product, or device is 
                experimental or nonconventional.
                    (B) That the experimental drug, biological product, 
                or device has not been approved, licensed, or cleared 
                for commercial distribution under section 505, 510(k), 
                or 515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262) for any 
                indication.
                    (C) The material risks generally recognized by a 
                reasonably prudent physician of the medical treatment's 
                side effects.
                    (D) An explanation of the medical treatment, 
                including the expected frequency and duration of the 
                treatment.
    (c) No Liability or Use of Outcomes.--
            (1) No liability.--Notwithstanding any other provision of 
        law, no liability shall lie against a producer, manufacturer, 
        distributor, prescriber, dispenser, possessor, or user of an 
        experimental drug, biological product, or device for the 
        production, manufacture, distribution, prescribing, dispensing, 
        possession, or use of an experimental drug, biological product, 
        or device that is in compliance, with subsection (a).
            (2) No use of outcomes.--Notwithstanding any other 
        provision of law, the outcome of any production, manufacture, 
        distribution, prescribing, dispensing, possession, or use of an 
        experimental drug, biological product, or device that was done 
        in compliance with subsection (a) shall not be used by a 
        Federal agency reviewing the experimental drug, biological 
        product, or device to delay or otherwise adversely impact 
        review or approval of such experimental drug, biological 
        product, or device.
    (d) Rules of Construction.--Nothing in this Act shall be construed 
to--
            (1) require a manufacturer or other person to make 
        available any experimental drug, biological product, or device; 
        or
            (2) prohibit a manufacturer or other person from receiving 
        compensation or recovering costs for the production, 
        manufacture, distribution, or sale of an experiment drug, 
        biological product, or device.
    (e) Definitions.--In this section:
            (1) Biological product.--The term ``biological product'' 
        has the meaning given to such term in section 351 of the Public 
        Health Service Act (42 U.S.C. 262).
            (2) Device; drug.--The terms ``device'' and ``drug'' have 
        the meanings given to such terms in section 201 of the Federal 
        Food, Drug, and Cosmetic Act (21 U.S.C. 321).
            (3) Experimental drug, biological product, or device.--The 
        term ``experimental drug, biological product, or device'' means 
        a drug, biological product, or device that--
                    (A) has successfully completed a phase 1 clinical 
                investigation;
                    (B) remains under investigation in a clinical trial 
                approved by the Food and Drug Administration; and
                    (C) is not approved, licensed, or cleared for 
                commercial distribution under section 505, 510(k), or 
                515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262).
            (4) Phase 1 clinical investigation.--The term ``phase 1 
        clinical investigation'' means a phase 1 clinical 
        investigation, as described in section 312.21 of title 21, Code 
        of Federal Regulations (or any successor regulations).
            (5) Terminal illness.--The term ``terminal illness'' has 
        the meaning given to such term in the State law specified in 
        subsection (a)(1)(B).

Ex Output:
Right to Try Act This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.  


Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Safe and Secure Federal Websites Act 
of 2015''.

SEC. 2. ENSURING FUNCTIONALITY AND SECURITY OF NEW FEDERAL WEBSITES 
              THAT COLLECT PERSONALLY IDENTIFIABLE INFORMATION.

    (a) Certification Requirement.--
            (1) In general.--Except as otherwise provided under this 
        subsection, an agency may not deploy or make available to the 
        public a new Federal PII website until the date on which the 
        chief information officer of the agency submits a certification 
        to Congress that the website is fully functional and secure.
            (2) Transition.--In the case of a new Federal PII website 
        that is operational on the date of the enactment of this Act, 
        paragraph (1) shall not apply until the end of the 90-day 
        period beginning on such date of enactment. If the 
        certification required under paragraph (1) for such website has 
        not been submitted to Congress before the end of such period, 
        the head of the responsible agency shall render the website 
        inaccessible to the public until such certification is 
        submitted to Congress.
            (3) Exception for beta website with explicit permission.--
        Paragraph (1) shall not apply to a website (or portion thereof) 
        that is in a development or testing phase, if the following 
        conditions are met:
                    (A) A member of the public may access PII-related 
                portions of the website only after executing an 
                agreement that acknowledges the risks involved.
                    (B) No agency compelled, enjoined, or otherwise 
                provided incentives for such a member to access the 
                website for such purposes.
            (4) Construction.--Nothing in this section shall be 
        construed as applying to a website that is operated entirely by 
        an entity (such as a State or locality) that is independent of 
        the Federal Government, regardless of the receipt of funding in 
        support of such website from the Federal Government.
    (b) Definitions.--In this section:
            (1) Agency.--The term ``agency'' has the meaning given that 
        term under section 551 of title 5, United States Code.
            (2) Fully functional.--The term ``fully functional'' means, 
        with respect to a new Federal PII website, that the website can 
        fully support the activities for which it is designed or 
        intended with regard to the eliciting, collection, storage, or 
        maintenance of personally identifiable information, including 
        handling a volume of queries relating to such information 
        commensurate with the purpose for which the website is 
        designed.
            (3) New federal personally identifiable information website 
        (new federal pii website).--The terms ``new Federal personally 
        identifiable information website'' and ``new Federal PII 
        website'' mean a website that--
                    (A) is operated by (or under a contract with) an 
                agency;
                    (B) elicits, collects, stores, or maintains 
                personally identifiable information of individuals and 
                is accessible to the public; and
                    (C) is first made accessible to the public and 
                collects or stores personally identifiable information 
                of individuals, on or after October 1, 2012.
            (4) Operational.--The term ``operational'' means, with 
        respect to a website, that such website elicits, collects, 
        stores, or maintains personally identifiable information of 
        members of the public and is accessible to the public.
            (5) Personally identifiable information (pii).--The terms 
        ``personally identifiable information'' and ``PII'' mean any 
        information about an individual elicited, collected, stored, or 
        maintained by an agency, including--
                    (A) any information that can be used to distinguish 
                or trace the identity of an individual, such as a name, 
                a social security number, a date and place of birth, a 
                mother's maiden name, or biometric records; and
                    (B) any other information that is linked or 
                linkable to an individual, such as medical, 
                educational, financial, and employment information.
            (6) Responsible agency.--The term ``responsible agency'' 
        means, with respect to a new Federal PII website, the agency 
        that is responsible for the operation (whether directly or 
        through contracts with other entities) of the website.
            (7) Secure.--The term ``secure'' means, with respect to a 
        new Federal PII website, that the following requirements are 
        met:
                    (A) The website is in compliance with subchapter II 
                of chapter 35 of title 44, United States Code.
                    (B) The website ensures that personally 
                identifiable information elicited, collected, stored, 
                or maintained in connection with the website is 
                captured at the latest possible step in a user input 
                sequence.
                    (C) The responsible agency for the website has 
                encrypted, masked, or taken other similar actions to 
                protect personally identifiable information elicited, 
                collected, stored, or maintained in connection with the 
                website.
                    (D) The responsible agency for the website has 
                taken reasonable efforts to minimize domain name 
                confusion, including through additional domain 
                registrations.
                    (E) The responsible agency requires all personnel 
                who have access to personally identifiable information 
                in connection with the website to have completed a 
                Standard Form 85P and signed a non-disclosure agreement 
                with respect to personally identifiable information, 
                and the agency takes proper precautions to ensure that 
                only the fewest reasonable number of trustworthy 
                persons may access such information.
                    (F) The responsible agency maintains (either 
                directly or through contract) sufficient personnel to 
                respond in a timely manner to issues relating to the 
                proper functioning and security of the website, and to 
                monitor on an ongoing basis existing and emerging 
                security threats to the website.
            (8) State.--The term ``State'' means each State of the 
        United States, the District of Columbia, each territory or 
        possession of the United States, and each federally recognized 
        Indian tribe.

SEC. 3. PRIVACY BREACH REQUIREMENTS.

    (a) Information Security Amendment.--Subchapter II of chapter 35 of 
title 44, United States Code, is amended by adding at the end the 
following:
``Sec. 3559. Privacy breach requirements
    ``(a) Policies and Procedures.--The Director of the Office of 
Management and Budget shall establish and oversee policies and 
procedures for agencies to follow in the event of a breach of 
information security involving the disclosure of personally 
identifiable information, including requirements for--
            ``(1) not later than 72 hours after the agency discovers 
        such a breach, or discovers evidence that reasonably indicates 
        such a breach has occurred, notice to the individuals whose 
        personally identifiable information could be compromised as a 
        result of such breach;
            ``(2) timely reporting to a Federal cybersecurity center, 
        as designated by the Director of the Office of Management and 
        Budget; and
            ``(3) any additional actions that the Director finds 
        necessary and appropriate, including data breach analysis, 
        fraud resolution services, identity theft insurance, and credit 
        protection or monitoring services.
    ``(b) Required Agency Action.--The head of each agency shall ensure 
that actions taken in response to a breach of information security 
involving the disclosure of personally identifiable information under 
the authority or control of the agency comply with policies and 
procedures established by the Director of the Office of Management and 
Budget under subsection (a).
    ``(c) Report.--Not later than March 1 of each year, the Director of 
the Office of Management and Budget shall report to Congress on agency 
compliance with the policies and procedures established under 
subsection (a).
    ``(d) Federal Cybersecurity Center Defined.--The term `Federal 
cybersecurity center' means any of the following:
            ``(1) The Department of Defense Cyber Crime Center.
            ``(2) The Intelligence Community Incident Response Center.
            ``(3) The United States Cyber Command Joint Operations 
        Center.
            ``(4) The National Cyber Investigative Joint Task Force.
            ``(5) Central Security Service Threat Operations Center of 
        the National Security Agency.
            ``(6) The United States Computer Emergency Readiness Team.
            ``(7) Any successor to a center, team, or task force 
        described in paragraphs (1) through (6).
            ``(8) Any center that the Director of the Office of 
        Management and Budget determines is appropriate to carry out 
        the requirements of this section.''.
    (b) Technical and Conforming Amendment.--The table of sections for 
subchapter II of chapter 35 of title 44, United States Code, is amended 
by adding at the end the following:

``3559. Privacy breach requirements.''.

Ex Output:
Safe and Secure Federal Websites Act of 2015 This bill establishes security and privacy requirements for new federal websites that collect personally identifiable information (PII) (i.e., information that can be used to distinguish or trace the identity of an individual or that is linked or linkable to an individual).  (Sec. 2) A federal agency may not deploy or make available to the public a new federal PII website until the agency's chief information officer (CIO) certifies to Congress that the website is fully functional and secure. The CIO must make such certification within 90 days after enactment of this Act. After such 90-day period, any new federal PII website that has not been certified must be rendered inaccessible until certification is submitted.  The prohibition does not apply to a website that is: (1) operated entirely by an entity that is independent of the federal government, or (2) in a development or testing phase (beta website). The exemption for beta websites applies only if: (1) a member of the public may access PII-related portions of the website only after executing an agreement that acknowledges the risks involved; and (2) no agency compelled, enjoined, or otherwise provided incentives for a member of the public to access such website.  The bill defines a "new federal PII website" as a website that: (1) is operated by (or under contract with) an agency; (2) elicits, collects, stores, or maintains PII and is accessible to the public; and (3) is first made accessible to the public and collects or stores PII on or after October 1, 2012. The bill also sets forth requirements that must be met to deem a new federal PII website as "secure." (Sec. 3) The Director of the Office of Management and Budget (OMB) must establish and oversee policies and procedures for federal agencies to follow in the event of a breach of information security involving the disclosure of PII, including: (1) notice, not later than 72 hours after discovery of a breach or possible breach, to individuals whose PII could be compromised; and (2) timely reporting to a federal cybersecurity center designated by the OMB and defined in this Act.  Agency heads must ensure that agency actions taken in response to a breach of information security involving the disclosure of PII comply with OMB policies and procedures established by this Act. The OMB must report to Congress, not later than March 1 of each year, on agency compliance with such policies and procedures.  A "federal cybersecurity center" is defined to include: (1) the Department of Defense Cyber Crime Center, (2) the Intelligence Community Incident Response Center, (3) the U.S. Cyber Command Joint Operations Center, (4) the National Cyber Investigative Task Force, (5) the Central Security Service Threat Operations Center of the National Security Agency, (6) the U.S. Computer Emergency Readiness Team, and (7) any center that the OMB determines is appropriate to carry out privacy breach notice and reporting requirements. 


Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Uniformed Services Medicare 
Subvention Demonstration Project Act''.

SEC. 2. DEFINITIONS.

    For purposes of this Act:
            (1) Medicare-eligible covered military beneficiary.--The 
        term ``medicare-eligible covered military beneficiary'' means a 
        beneficiary under chapter 55 of title 10, United States Code, 
        including a beneficiary under section 1074(a) of such title, 
        who is entitled to benefits under part A of title XVII of the 
        Social Security Act (42 U.S.C. 1395 et seq.).
    (2) TRICARE program.--The term ``TRICARE program'' means the 
managed health care program that is established by the Secretary of 
Defense under the authority of chapter 55 of title 10, United States 
Code, principally section 1097 of such title, and includes the 
competitive selection of contractors to financially underwrite the 
delivery of health care services under the Civilian Health and Medical 
Program of the Uniformed Services.
    (3) Military treatment facility.--The term ``military treatment 
facility'' means a facility referred to in section 1074(a) of title 10, 
United States Code.

SEC. 3. ESTABLISHMENT.

    (a) In General.--Not later than 180 days after the date of the 
enactment of this Act, the Secretary of Defense and the Secretary of 
Health and Human Services shall jointly establish a demonstration 
project to provide the Department of Defense with reimbursement, in 
accordance with section 4, from the medicare program under title XVII 
of the Social Security Act (42 U.S.C. 1395 et seq.) for health services 
provided to certain medicare-eligible covered military beneficiaries.
    (b) Geographic Regions.--The demonstration project established 
under this section shall be conducted in one or more geographic regions 
in which the TRICARE program has been implemented.
    (c) Duration.--The demonstration project established under this 
section shall be conducted for a period not to exceed 2 years.
    (d) Reporting.--
            (1) In general.--
                    (A) First annual report.--Not later than 15 months 
                after the demonstration project under this section has 
                been established, the Secretary of Defense and the 
                Secretary of Health and Human Services shall jointly 
                submit to Congress a report including the information 
                described in paragraph (2).
                    (B) Final report.--Not later than 90 days after the 
                termination of the demonstration project, the Secretary 
                shall jointly submit to Congress a final report 
including the information described in paragraph (2).
            (2) Information described.--The information described in 
        this paragraph includes the following:
                    (A) The number of medicare-eligible covered 
                military beneficiaries opting to participate in the 
                demonstration project established under this section 
                instead of receiving health benefits through another 
                health insurance plan (including through the medicare 
                program).
                    (B) Whether, and in what manner, easier access to 
                the military treatment system affects the number of 
                medicare-eligible covered military beneficiaries 
                receiving health benefits under the medicare program.
                    (C) A list of the health insurance plans and 
                programs that were the primary payers for medicare-
                eligible covered military beneficiaries during the year 
                prior to such beneficiary's participation in the 
                demonstration project and the distribution of 
                enrollment of such beneficiaries in such plans and 
                programs.
                    (D) The total number of medicare-eligible covered 
                military beneficiaries who participated in the project 
                during the preceding year and the number of such 
                beneficiaries who were entitled to benefits under part 
                A of title XVIII of the Social Security Act (42 U.S.C. 
                1395 et seq.) and were not enrolled under part B of 
                such title.
                    (E) An identification of cost-shifting (if any) 
                among medical care programs as a result of the 
                demonstration project and a description of the nature 
                of any such cost-shifting.
                    (F) An analysis of how the demonstration project 
                affects the overall accessibility of the military 
                treatment system and the amount of space available for 
                point-of-service care and a description of the 
                unintended effects (if any) upon the normal treatment 
                priority system.
                    (G) A description of the difficulties (if any) 
                experienced by the Department of Defense in managing 
                the demonstration project.
                    (H) A description of the effects of the 
                demonstration project on military treatment facility 
                readiness and training and the probable effects of the 
                project on overall Department of Defense medical 
                readiness and training.
                    (I) A description of the effects that the 
                demonstration project, if permanent, would be expected 
                to have on the overall budget of the military health 
                care system and the budgets of individual military 
                treatment facilities.
                    (J) Whether the demonstration project affects the 
                cost to the Department of Defense of prescription drugs 
                or the accessibility, availability, and cost of such 
                drugs to program beneficiaries.

SEC. 4. REIMBURSEMENT AMOUNTS.

    (a) Payment to Department of Defense.--The Secretary of Health and 
Human Services shall make monthly payments to the Department of Defense 
from the Federal Hospital Insurance Trust Fund and the Federal 
Supplementary Medical Insurance Trust Fund (allocated between each 
Trust Fund in an amount to be determined by the Secretary of Health and 
Human Services based on the relative weight that benefits from each 
Trust Fund contribute to the amounts determined under this subsection) 
in an amount equal to the sum of--
            (1) the payments determined under subsection (b) with 
        respect to medicare-eligible covered military beneficiaries who 
        are enrolled in the TRICARE program; and
            (2) the payments determined under subsection (c) with 
        respect to such beneficiaries who are not enrolled in the 
        TRICARE program.
    (b) TRICARE Payments.--
            (1) In general.--The amount of payment determined under 
        this subsection is an amount equal to \1/12\ of the amount 
        determined under paragraph (2) for each medicare-eligible 
        covered military beneficiary enrolled during the year in the 
        TRICARE program in a geographic region in which the 
        demonstration project is in operation, but only if such 
        beneficiary's enrollment is in excess of the minimum enrollment 
        number determined under subsection (d)(1)(A) for such 
        geographic region.
            (2) Amount determined.--The amount determined under this 
        paragraph is an amount equal to--
                    (A) in the case of an individual entitled to 
                benefits under part A and enrolled under part B of 
                title XVIII of the Social Security Act, 93 percent of 
                the average adjusted per capita cost determined under 
                section 1876(a)(4) of the Social Security Act (42 
                U.S.C. 1395mm(a)(4)) for such year; or
                    (B) in the case of an individual entitled to 
                benefits under part A and not enrolled under part B of 
                such title, an amount equal to the amount determined 
                under subparagraph (A) attributable to services covered 
                by and expenses otherwise reimbursable under part A of 
                such title only.
    (c) Treatment at a Military Treatment Facility.--The amount of 
payment determined under this subsection is an amount equal to the sum 
of the Secretary's estimates of the amounts determined for each health 
service (using a DRG equivalent and fee schedule equivalent scale 
developed by the Secretary of Health and Human Services) provided 
during the month for which the payment is made under subsection (a) to 
each medicare-eligible covered military beneficiary (other than a 
beneficiary who is enrolled in the TRICARE program) in a military 
treatment facility located in a geographic region in which the 
demonstration project is in operation, but only if such level is in 
excess of \1/12\ of the minimum level of health services described 
under subsection (d)(1)(B) for such geographic region.
    (d) Establishment of Base Level of Coverage.--
            (1) In general.--Prior to the establishment of the 
        demonstration project under this Act and subject to paragraph 
        (2), the Secretary of Defense and the Secretary of Health and 
        Human Services shall jointly estimate, based on the best 
        available data--
                    (A) a minimum enrollment number of medicare-
                eligible covered military beneficiaries who are 
                required to enroll in the TRICARE program during a year 
                in each geographic region in which the demonstration 
                project is in operation before the Department of 
                Defense may receive payment under subsection (a)(1); 
                and
                    (B) a minimum level of health services (using a DRG 
                equivalent and fee schedule equivalent scale developed 
                by the Secretary of Health and Human Services) provided 
                to medicare-eligible covered military beneficiaries 
                (other than beneficiaries enrolled in the TRICARE 
                program) during a year through a military treatment 
                facility in each geographic region in which the 
                demonstration project is in operation before the 
                Department of Defense may receive payment under 
                subsection (a)(2).
            (2) Determination of baseline costs.--The Secretary of 
        Defense and the Secretary of Health and Human Services shall 
establish the minimum enrollment number under paragraph (1)(A) and the 
minimum level of health services under paragraph (1)(B) such that the 
projected expenditures by the Department of Defense for such number of 
medicare-eligible covered military beneficiaries and such level of 
services provided to such beneficiaries by the Department of Defense is 
equivalent to the projected expenditures that would have been made by 
the Department for such beneficiaries if the demonstration project 
under this Act had not been established.
            (3) Upper reimbursement limits.--The Secretary of Defense 
        and the Secretary of Health and Human Services shall jointly 
        establish a maximum number of medicare-eligible covered 
        military beneficiaries and maximum level of health services for 
        which payment may be made by the Secretary of Health and Human 
        services under subsection (a).
    (e) TRICARE Program Enrollment Fee Waiver.--The Secretary of 
Defense shall waive the enrollment fee applicable to any individual 
enrolled in the TRICARE program for whom reimbursement in the amount 
determined under subsection (b)(2)(A) is received under subsection 
(b)(1).

SEC. 5. MEDICARE SUBVENTION FUND.

    (a) Establishment.--There is hereby established in the Treasury of 
the United States a revolving fund known as the Medicare Subvention 
Fund (hereafter in this section referred to as the ``Fund'').
    (b) Use of Funds.--The Fund shall be available to the Secretary of 
Defense, as so provided in appropriations Acts from funds otherwise 
appropriated to the Department of Defense, and without fiscal year 
limitation--
            (1) to make payments to the Secretary of Health and Human 
        Services for deposit into the Federal Hospital Insurance Trust 
        Fund and the Federal Supplementary Medical Insurance Trust Fund 
        in order to reimburse such Funds for additional costs to such 
        Trust Funds resulting from the operation of the demonstration 
        project established under this Act;
            (2) to provide for the participation of medicare-eligible 
        covered military beneficiaries in excess of the maximum 
        enrollment number and maximum level of health services 
        established under section 4(d)(1);
            (3) to provide for payment of administrative expenses 
        associated with the demonstration project established under 
        this Act; and
            (4) if amounts are available in the Fund after expenditures 
        are made under paragraphs (1) through (3), for any other lawful 
        purpose for which the Secretary of Defense may expend funds.
    (c) No Funds Available.--The Secretary of Defense may, if 
inadequate amounts are available in the Fund, limit the enrollment of 
medicare-eligible covered military beneficiaries in the demonstration 
project established under this Act.
    (d) Authorization of Appropriations.--For each of fiscal years 1997 
and 1998, there are authorized to be appropriated from funds otherwise 
appropriated to the Department of Defense, for deposit in the Fund such 
sums as may be necessary to carry out the purposes described in 
paragraphs (1) through (3) of subsection (c). Any amounts appropriated 
in accordance with this subsection shall not be taken into account in 
establishing appropriations levels for the Department of Defense health 
affairs budget.

Ex Output:

Uniformed Services Medicare Subvention Demonstration Project Act - Directs the Secretaries of Defense and Health and Human Services (HHS) to jointly establish a demonstration project to provide the Department of Defense (DOD) with reimbursement, under provisions of title XVIII (Medicare) of the Social Security Act, for health services provided to Medicare-eligible covered military beneficiaries who participate in the project and receive such services through the managed care option of the TRICARE program (a DOD managed health care program).  Requires the project to be conducted during the three-year period beginning on January 1, 1997, in two or more regions in which the TRICARE program has been implemented.  Requires inclusion in the project of a provision for expansion to incorporate health care services provided to such beneficiaries under the fee-for-services options of the TRICARE program if the Secretaries determine that such expansion is feasible and advisable. 
Requires the Secretaries to submit to the Congress an interim and final report on project participants and on the project's effects on military medical care access, readiness, and training. 
Directs the HHS Secretary to make monthly payments to DOD from the Federal Hospital Insurance Trust Fund and the Federal Supplementary Medical Insurance Trust Fund representing appropriate reimbursement amounts.  Provides for the determination of such amounts. 
Directs the Secretaries to:  (1) establish minimum and maximum project enrollment levels; and (2) determine baseline costs of such care and coverage.  Directs the Secretary of Defense to waive the enrollment fee for individuals enrolled in a TRICARE program participating in the project. 
Requires the Comptroller General, for each project year, to submit to the Secretaries and the Congress a report on the extent to which costs under the TRICARE program and the Medicare program have increased as a result of the project.  Directs the Secretaries to modify the project at the end of each year to correct for any discrepancy between cost targets and actual spending under the project.